Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure

Circulation

Volumn 103, Issue 2, 2001, Pages 220-225

  Gullestad, Lars ^a   Aass, Halfdan ^a   Fjeld, Jan G ^a   Wikeby, Lisbeth ^a,b   Andreassen, Arne K ^a   Ihlen, Halfdan ^a   Simonsen, Svein ^a   Kjekshus, John ^a   Nitter Hauge, Sigurd ^a   Ueland, Thor ^a   Lien, Egil ^b   Frøland, Stig S ^a   Aukrust, P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Heart failure; Immune system; Inflammation; Interleukins

Indexed keywords

ATRIAL NATRIURETIC FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 14344277564     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.2.220     Document Type: Article

References (28)

1. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart
2. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
3. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
4. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure
5. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
6. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in adult mammalian heart
7. Tumor necrosis factor α-induced apoptosis in cardiac myocytes
8. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive dysfunction and remodeling in rats
9. Manipulating the immune system with immune globulin
10. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders
11. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy
12. Immunomodulatory effect of immunoglobulins
13. Mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
14. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
15. Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
16. Administration of intravenous immunoglobulin (IVIG) in vivo: Down-regulatory effects on the IL-I system
17. A new color M-mode index of diastolic filling compared with radionuclide ventriculography
18. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
19. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy
20. Inhibition of toxic necrolysis by blockade of CD95 with human intravenous immunoglobulin
21. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
22. Vasoactive side effects of intravenous imunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase
23. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-α activity in patients with human immunodeficiency virus type 1 infection
24. Protective role of interleukin-10 in atherosclerosis
25. Gamma-globulin treatment of acute myocarditis in the pediatric population
26. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for further research
27. Human monocytes/macrophages release TNFα in response to Ox-LDL
28. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium